PsychoGenics stands at the forefront of preclinical mental illness research. Our state-of-the-art facilities, coupled with predictive rodent models and a large catalog of behavioral assays is unmatched in the industry. Our in-house-developed SmartCube® platform exemplifies our innovation and commitment to industrializing phenotypic drug discovery for mental illness therapies and providing data-rich insights. Partnering with us means tapping into an unparalleled blend of technological sophistication, bespoke solutions, and a stellar track record in mental illness drug discovery.
Harnessing the Power of Rodent Models to Test Treatments for Mental Illness
We offer a broad range of support for preclinical studies of several mental illnesses, enabling you to gain a comprehensive understanding of disease mechanisms and find your potential breakthrough.
Explore our areas of specialization:
Partner with PsychoGenics and Accelerate Your Preclinical Mental Illness Research
We believe in the power of collaboration and work closely with you to design highly customized studies that align with your specific research goals. PsychoGenics’ team of early-stage mental illness drug development experts advise you on the most suitable approach, ensuring a tailored experience and the best possible outcome.
With our deep understanding of rodent models, advanced technologies, and commitment to customized solutions, we offer the ideal partnership for driving your mental illness drug development program.